| Mylan Pharma GmbH - Influvac, Injektionssuspension | | 00485 | | 32 | | Influvac | | Injektionssuspension | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 07.08.2019 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus-Stamm A/Brisbane/02/2018 (H1N1)-like: reassortant virus A/Brisbane/02/2018, IVR-190) 15 µg, haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Kansas/14/2017 (H3N2)-like: reassortant virus A/Kansas/14/2017, NYMC X-327) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant virus B/Maryland/15/2016 NYMC BX-69A) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: natrii citras dihydricus max. 1 mg, cetrimidum max. 15 µg, formaldehydum max. 10 µg, gentamicini sulfas max. 1 ng, tylosini tartras nihil, hydrocortisonum nihil, polysorbatum 80 nihil, ovalbuminum max. 0.1 µg, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | | | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| No entries have been found. |
|
|
